Titan Biotech Ltd Fair Value
TITANBIOTECHLTD · Chemicals · Current price
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹54 | 18% ROE fading to 13% over ~10 yrs, on ₹44 book |
| Relative P/E | ₹323 | EPS × 44.6 peer-median P/E |
| Graham floor | ₹85 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is Titan Biotech Ltd undervalued?
We couldn't compute a reliable fair value for Titan Biotech Ltd from the available data. This usually means key inputs (earnings, book value, or cash flow) are missing or inconsistent.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹54), Relative P/E (₹323), Graham floor (₹85). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹54 (bear) to ₹130 (base) to ₹323 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on Titan Biotech Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.